HEMIO URGANIC LIMITED

CIN: - L24231GJ1992PLC018224

Address: - 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001 Email ID: -drdineshpatel@rediffmail.com, Website: - www.hemoorganichtd.com

Date: September 15, 2020

To, BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, Mumbai - 400 001.

Dear Sir,

Sub: Submission of Unaudited Financial Result of the Company for the quarter ended on June 30, 2020 along with Limited Review Report

Ref: Hemo Organic Limited (Security ID: HEMORGANIC, Security Code: 524590)

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

- 1. Unaudited Financial Results for the quarter ended on June 30, 2020
- 2. Limited Review Report

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Hemo Organic Limited

Dr. Dinesh Patel

pr

Chairman and Managing Director

DIN: 00481641

Place: Anand

HEMO ORGANIC LIMITED

CIN: L24231GJ1992PLC018224

Registered Office: 8-A, GULNAR, CHINAR - GULNAR APPT, V V NAGAR ROAD ANAND GJ 388001 STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30th June, 2020

(Rs. In lakh)

		Quarter ended on			Year Ended on	
	Particulars	30-06-2020 31-03-2020 30-06-2019			31-03-2020	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
:	Revenue from operations		13.02	3.97	27.72	
2	Other income				27.72	
3	Total Income (1+2)	-	13.02	3.97	21.12	
4	Expenses				19.03	
	a. Purchases		8.98	3.46	19.03	
	b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	0.12	0.07	
	c. Employee benefits expense	0.65	0.65	0.64	2.58	
	d. Finance costs	19		-		
	e. Depreciation & amortisation expense				0.22	
	f. Other expenses	0.56	0.81	5.83	8.22	
	Total Expenses	1.20	10.44	10.05	29.90	
5	Profit / (Loss) before exceptional items and tax (3	(1.20)	2.58	(6.08)	(2.18)	
6	Exceptional items			-	(2.40)	
7	Profit / (Loss) before tax (5+6)	(1.20)	2.58	(6.08)	(2.18)	
8	Tax expense:		2 1			
	Current tax					
	Deferred tax		- 1-	3		
9	Profit (Loss) for the period from continuing operations (7-8)	(1.20)	2.58	(6.08)	(2.18	
10	Profit/(loss) from discontinuing operations before Tax			1		
11	Tax expense of discontinuing operations				and the same of	
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)					
13	Profit / (Loss) for the period (9+12)	(1.20)	2.58	(6.08)	(2.18	
14	Other Comprehensive Income					
	Items that will not be reclassified subsequently to profit or loss					
	Income tax relating to items that will not be reclassified to profit or loss					
7	Income tax relating to items that will be reclassified to profit or loss					
	Other Comprehensive Income, net of tax					
15	Total Comprehensive Income for the period	(1.20)	2.58	(6.08)	(2.18	
16	Details of equity share capital					
	Paid-up equity share capital	346.59	346.59	346.59	346.5	
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/		
17	Earnings Per Share of Rs. 10/- each				10.10	
	Basic	(0.03	0.00	10.10		
					(0.0	
	- Diluted Earnings Per Share of Rs. 10/- each	(0.03	0.07	7 (0.18	(0.0	
17	(for discontinued operations) Basic					
	- Diluted					
	Earnings Per Share of Rs. 10/- each					
18	(for discontinued & continuing operations)					
	· Basic	(0.0)	0.0	07 (0.1)	8) (0)	
	· Diluted	(0.0)				

Place: Ahmedabad Date: 15/09/2020

ordanie Hen

Hemo Organic Limited


Dineshbhai Patel Managing Director DIN:00481641

Notes:	Notes:			
1	The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on September 15, 2020			
2	The financial results of the company have been prepared in accordance with Indian Accounting Standards prescribed under			
	Section 133 of the companies Act, 2013 read with relevant rules there under and in terms with regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) regulations 2015 and SEBI circular dated 5th July 2016.			
3	The statutory Auditors of the company have carried out a "Limited Review" of the above result as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IND AS compliant corresponding figures of the previous year have not been subject to review, however the company's management has exercised necessary due diligence to ensure that such financial results provide true and fair view.			
4	COVID-19 is significantly impacting business operation of the companies, by way of interruption in production, supply chain disruption, unavailability of personnel, closure / lock down of production facilities etc. On 24th March 2020, the Government of India ordered a nationwide lockdown for 21 days which further got extended till 3rd May 2020 to prevent community spread of COVID-19 in India resulting in significant reduction in economic activities.			
5	Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities any.			
6	Previous period figures have been reclassified / regrouped wherever considered necessary to confirm to the current period figures.			
	By order of the Board			

Place: Ahmedabad Date: 15/09/2020



Dineshbhai Patel Managing Director DIN:00481641



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS OF HEMO ORGANIC LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE PERIOD ENDED 30th JUNE, 2020

To,

The Board of Directors, Hemo Organic Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Hemo Organic Limited for the quarter ended 30th June, 2020, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FCA/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, except as specified in Qualified Opinion para, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

H.O.: 5, 1st Floor, Devashish Complex, Nr. Bavarchi Rest., Off C.G. Road, Ahmedabad 380006

Branch: 405, Onyx - 2, Besides Navchetan School, Paldi Cross Road, Ahmedabad - 380007

:www.maakadvisors.com :079-4032-3758

Emphasis on Matter:

- 1. The Company has not charged depreciation on the fixed assets during the year and accordingly provision of Indian Accounting Standards relating to depreciation and Deferred Tax Asset / Liabilities have not been followed. The management represented that the amount of depreciation being negligible the same has been not been incorporated.
- 2. The closing stock has been calculated and certified by management only and we have not been provided with the basis of calculation.
- 3. The Govt. of India ordered a nationwide lockdown on 24th March 2020 in view of Covid'19 pandemic consequently there was significant reduction in economic activities in the country. The Company has considered the possible effect on the carrying amounts of investments, inventories, receivable and other current asset of company due to Covid-19 pandemic. The Company as on the date approval of these financial results has used internal and external sources on the future performance of the company. The Company based on current estimates expect that carrying amount of the company's assets are fully recoverable. Further the Company believes that impact of Covid-19 pandemic on the company's financial statements is temporary and not material.

Qualified Opinion:

- We have not been provided with the balance confirmation or any other details for the trade receivable and trade payable shown in the books of accounts.
- 2. We have not been able to verify the transactional documents relating bank statements. Four out of five account are not shown to us for verification. According to the management, the other accounts are dormant and therefore the same have not been collected from bank.

Date:15/09/2020 Place: Ahmedabad

riace. Allineuabau

UDIN: 20137390AAAAEM6107

For, M A A K & Associates (Chartered Accountants)

F.R.N.: 135024W

CA Archit Shah (Partner) Mem. No.:137390